Page last updated: 2024-12-06

acetylgalactosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-acetylgalactosamine (GalNAc) is a derivative of galactose, a simple sugar. It is found in many biological molecules, including glycoproteins, glycolipids, and glycosaminoglycans. GalNAc is important for cell signaling, cell adhesion, and immune responses. It is often linked to serine or threonine residues in proteins through O-glycosylation. GalNAc is also involved in the synthesis of chondroitin sulfate, a major component of cartilage. The study of GalNAc is important for understanding its roles in these processes and for developing new therapies for diseases that involve glycosylation.'

capsid protein, San Miguel sea lion virus: amino acid sequence given in first source; from SMSV serotypes 1 & 4 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetyl-beta-D-galactosamine : An N-acetyl-D-galactosamine having beta-configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Acetylgalactosamine: The N-acetyl derivative of galactosamine. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID440552
CHEMBL ID39064
CHEBI ID28497
SCHEMBL ID152744
MeSH IDM0000188
PubMed CID35717
CHEMBL ID469447
CHEBI ID28037
SCHEMBL ID29838
MeSH IDM0000188

Synonyms (101)

Synonym
2-acetamido-2-deoxy-beta-d-galactopyranose
2-acetamido-2-deoxy-beta-d-galactopyranoside
beta-galnac
bgalnac
CHEBI:28497 ,
C05021
n-acetyl-beta-d-galactosamine
1BCJ
2Z8E
CHEMBL39064
n-[(2r,3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
A812593
n-[(2r,3r,4r,5r,6r)-6-(hydroxymethyl)-2,4,5-tris(oxidanyl)oxan-3-yl]ethanamide
147995-09-3
capsid protein, san miguel sea lion virus
einecs 217-321-9
beta-d n-acetylgalactosamine
SCHEMBL152744
14131-60-3
.beta.-d-n-acetylgalactosamine
n-acetyl-.beta.-d-galactosamine
2-deoxy-2-acetamido-.beta.-d-galactopyranose
galactopyranose, 2-acetamido-2-deoxy-, .beta.-d-
KM15WK8O5T ,
.beta.-d-galactopyranose, 2-(acetylamino)-2-deoxy-
.beta.-n-acetyl-d-galactosamine
unii-km15wk8o5t
2-(acetylamino)-2-deoxy-b-d-galactopyranose
n-acetyl-b-d-galactosamine
beta-d-2-acetamido-2-deoxy-galactopyranose
beta-n-acetyl-delta-galactosamine
2-deoxy-2-acetamido-beta-d-galactopyranose
beta-n-acetylgalactosamine
2-deoxy-2-acetamido-b-d-galactopyranose
2-deoxy-2-acetamido-beta-delta-galactopyranose
b-n-acetylgalactosamine
beta-n-acetyl-d-galactosamine
b-n-acetyl-d-galactosamine
beta-delta-2-acetamido-2-deoxy-galactopyranose
b-d-2-acetamido-2-deoxy-galactopyranose
2-(acetylamino)-2-deoxy-beta-d-galactopyranose
130851-15-9
n-((2r,3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)acetamide
Q27096368
DTXSID601260928
galactopyranose, 2-acetamido-2-deoxy-, beta-d-
14215-68-0
O_FULL_01000000000000_GS_25
2-acetamido-2-deoxy-d-galactopyranose
d-galnac
CHEBI:28037 ,
2-acetamido-2-deoxy-d-galactose
n-acetyl-d-chondrosamine
C01132
galnac ,
n-acetylgalactosamine
n-acetyl-d-galactosamine ,
n-acetyl-d-galactosamine, ~98%
A-1170
acetylgalactosamine
A1245
n-[(3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
CHEMBL469447
A807857
n-[(2r,3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)-3-oxanyl]acetamide
2-acetamido-2-deoxygalactopyranose
1136-42-1
galactopyranose, 2-acetamido-2-deoxy-
n-((3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-3-yl)acetamide
AKOS016003462
EPITOPE ID:130648
AM84632
SCHEMBL29838
2-deoxy-2-acetamido-galactopyranoside
2-deoxy-2-acetamido-d-galactopyranose
2-acetamido-2-deoxy-d-galactopyranoside
2-acetamido-2-deoxy-galactose
2-deoxy-2-acetamido-d-galactose
2-acetamido-2-deoxy-galactopyranose
2-deoxy-2-acetamido-galactose
n-acetyl-galactosamine
2-deoxy-2-acetamido-galactopyranose
2-acetamido-2-deoxy-galactopyranoside
2-deoxy-2-acetamido-d-galactopyranoside
2-(acetylamino)-2-deoxyhexopyranose #
acetamido-2-deoxy-d-galactopyranose, 2-(rg)
6082-29-7
mfcd00065372
2-acetamido-2-desoxy-d-galactopyranose
n-[(3r,4r,5r,6r)-2,4,5-trihydroxy-6-methylol-tetrahydropyran-3-yl]acetamide
n-[(3r,4r,5r,6r)-6-(hydroxymethyl)-2,4,5-tris(oxidanyl)oxan-3-yl]ethanamide
CS-0207868
Q27103467
AS-12141
S11316
A881021
acetamido-2-deoxy-d-galactopyranose,2-(rg)
n-((3r,4r,5r,6r)-2,4,5-trihydroxy-6-(hydroxymethyl)-tetrahydro-2h-pyran-3-yl)acetamide
EN300-7366607
n acetyl d galactosamin
wurcs=2.0/1,1,0/(a2112h-1x_1-5_2*ncc/3=o)/1/

Research Excerpts

Overview

N-acetylgalactosamine (GalNAc) is a monosaccharide widely encountered in glycolipids, proteoglycans and glycoproteins. GalNAc containing sugar residues seem to be essential for initial adherence of respiratory bacteria to the surface of epithelial cells.

ExcerptReferenceRelevance
"N-acetylgalactosamine (GalNAc) is an important constituent of mucins and GalNAc containing sugar residues seem to be essential for initial adherence of respiratory bacteria to the surface of epithelial cells."( Bacterial adherence in otitis media: determination of N-acetylgalactosamine (GalNAc) residues in the submucosal glands and surface epithelium of the normal and diseased Eustachian tube.
Cayé-Thomasen, P; Friis, M; Kirkeby, S; Mikkelsen, HB,
)
0.94
"N-acetylgalactosamine kinase is a member of the GHMP family of small molecule kinases which catalyses the ATP-dependent phosphorylation of N-acetylgalactosamine. "( N-acetylgalactosamine kinase: a naturally promiscuous small molecule kinase.
Kristiansson, H; Timson, DJ, 2012
)
1.82
"N-Acetylgalactosamine (GalNAc) is a monosaccharide widely encountered in glycolipids, proteoglycans, and glycoproteins; once taken up by cells it can be converted through a salvage pathway to UDP-GalNAc, which is further used by glycosyltransferases to build glycans."( Evaluation of analogues of GalNAc as substrates for enzymes of the mammalian GalNAc salvage pathway.
Bourgeaux, V; Piller, F; Piller, V; Pouilly, S, 2012
)
0.94

Toxicity

ExcerptReferenceRelevance
" While numerous attempts to improve the efficiency of siRNA delivery have been reported, only a few studies of the mechanism of LNP-mediated toxicity and attempts to develop safe LNPs in vivo have been reported, in spite of the significance of such systems, in the light of treatment and clinical applications."( Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Harashima, H; Kohara, M; Matsui, H; Munakata, T; Sato, R; Sato, Y; Yamamoto, N, 2017
)
0.46
" The highly toxic compounds showed the greatest amount of metabolites and a low degree of tissue accumulation."( Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
Braendli-Baiocco, A; Brink, A; Dzygiel, P; Festag, M; Fischer, G; Hetzel, U; Husser, C; Kipar, A; Koller, E; Lenz, B; Mihatsch, MJ; Romero-Palomo, F; Schadt, S; Sewing, S; Steinhuber, B; Tessier, Y; Winter, M, 2021
)
0.62
"Upregulation of hepatic delta-aminolevulinic acid synthase 1 with accumulation of potentially toxic heme precursors delta-aminolevulinic acid and porphobilinogen is fundamental to the pathogenesis of acute hepatic porphyria."( Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Aguilera-Peiró, P; Anderson, DKE; Balwani, M; Bonkovsky, HL; Gouya, L; Hua, Z; Ko, JJ; Kuter, DJ; Monroy, S; Montgomery Bissell, D; Oh, J; Parker, C; Ritchie, B; Sardh, E; Stein, PE; Sweetser, MT; Ventura, P, 2022
)
0.72
" Endpoints included annualized attack rate, urinary delta-aminolevulinic acid and porphobilinogen levels, hemin use, daily worst pain, quality of life, and adverse events."( Efficacy and safety of givosiran for acute hepatic porphyria: 24-month interim analysis of the randomized phase 3 ENVISION study.
Aguilera-Peiró, P; Anderson, DKE; Balwani, M; Bonkovsky, HL; Gouya, L; Hua, Z; Ko, JJ; Kuter, DJ; Monroy, S; Montgomery Bissell, D; Oh, J; Parker, C; Ritchie, B; Sardh, E; Stein, PE; Sweetser, MT; Ventura, P, 2022
)
0.72
" No toxicities or adverse effects were observed in any cohort receiving inclisiran, either alone or in combination."( The N-Acetylgalactosamine-conjugated small interfering RNA inclisiran can be coadministered safely with atorvastatin in cynomolgus monkeys resulting in additive low-density lipoprotein cholesterol reductions.
Brown, AP; Kallend, D; Lehoux, D; Wijngaard, PLJ; Zerler, B, 2023
)
1.39

Pharmacokinetics

ExcerptReferenceRelevance
" This phase I study evaluated the safety, pharmacokinetic, and pharmacodynamic profile of subcutaneously (SC) administered givosiran in patients with acute intermittent porphyria, the most common AHP type."( Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Agarwal, S; Clausen, VA; Goel, V; Habtemariam, BA; Kim, JB; Robbie, GJ; Simon, AR, 2020
)
0.56
" Vutrisiran was rapidly absorbed (peak plasma concentration 3-5 hours post dose), had a short plasma half-life (4."( Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects.
Attarwala, H; Clausen, VA; Garg, P; Goel, V; Habtemariam, BA; Karsten, V; Melch, M; Robbie, GJ; Sweetser, MT; Vaishnaw, AK; Vest, J, 2021
)
0.85
" SIGNIFICANCE STATEMENT: Pharmacokinetic modeling of JNJ-73763989 liver and plasma concentration-time data in mice indicated that the proportion of JNJ-73763989 reaching the liver may be increased by administering lower subcutaneous doses compared to higher intravenous doses."( Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated-Hepatitis B Virus-Infected Mice.
Dosne, AG; Goeyvaerts, N; Perez-Ruixo, JJ; Sandra, L; T'jollyn, H; Vermeulen, A, 2022
)
0.98
" To this end, we collected and analyzed pharmacokinetic data from the literature regarding nine GalNAc-siRNAs."( Plasma Pharmacokinetics of N-Acetylgalactosamine-Conjugated Small-Interfering Ribonucleic Acids (GalNAc-Conjugated siRNAs).
Antonsson, M; Cardilin, T; Gennemark, P; Sten, S, 2023
)
1.2

Compound-Compound Interactions

ExcerptReferenceRelevance
" This study is aimed at discriminating between them, on the basis of the degree of acetylation and the acceptor sugars, by means of lectins combined with neuraminidase digestion and treatment with oxidizing and deacetylating agents."( Sialic acids in the chicken anterior lingual glands detected by lectins combined with enzymatic degradation and oxidizing agents.
Ceccarelli, P; Menghi, G; Scocco, P, 1995
)
0.29
"To understand the cytochemical properties of epididymal epithelial cells, the characteristics of glycoconjugates in the mouse epididymis were examined using the technique of lectin histochemistry combined with immunohistochemistry."( Cell- and region-specific expression of sugar chains in the mouse epididymal epithelium using lectin histochemistry combined with immunohistochemistry.
Fukui, T; Sawaguchi, A; Tajiri, S; Yoshinaga, K, 2012
)
0.38
" RNAi therapeutics, such as givosiran, have a low liability for drug-drug interactions (DDIs) because they are not metabolized by cytochrome 450 (CYP) enzymes, and do not directly inhibit or induce CYP enzymes in the liver."( A Drug-Drug Interaction Study Evaluating the Effect of Givosiran, a Small Interfering Ribonucleic Acid, on Cytochrome P450 Activity in the Liver.
Agarwal, S; Clausen, VA; Harper, P; Najafian, N; Robbie, GJ; Sardh, E; Simon, AR; Vassiliou, D, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" After subcutaneous dosing, absolute bioavailability was complete and flip-flop kinetics were observed."( Plasma and Liver Pharmacokinetics of the N-Acetylgalactosamine Short Interfering RNA JNJ-73763989 in Recombinant Adeno-Associated-Hepatitis B Virus-Infected Mice.
Dosne, AG; Goeyvaerts, N; Perez-Ruixo, JJ; Sandra, L; T'jollyn, H; Vermeulen, A, 2022
)
0.98

Dosage Studied

ExcerptRelevanceReference
" A dose-response curve for these lines can be demonstrated with maximal stimulation at 16 and 32 micrograms per ml and inhibition at 75 to 250 micrograms per ml PHA."( Phytohemagglutinin effects on cultured human neural crest tumors.
Helson, L, 1979
)
0.26
"A wide dose-response curve and the inhibitory effect on mitogenicity of specific antitoxin suggest that polyclonal lymphocyte activation by staphylococcal enterotoxin requires direct interaction of toxin with lymphocyte receptors of low avidity for the protein."( Evidence for cell-receptor activity in lymphocyte stimulation by staphylococcal enterotoxin.
Leatherman, DL; Metzger, JF; Warren, JR, 1975
)
0.25
" The release reaction is induced in the same dosage range as the agglutination of human red blood cells occurs."( Histamine release from rat mast cells induced by the lectin from the snail, Cepaea nemoralis L. - a counterpart to the triggering action of polycations?
Schnitzler, S, 1982
)
0.26
" A dose-response study conducted using 10-160 micrograms/ml, of GS I-A4 demonstrated significant dose-related toxicity against LS174t and SW1116 cells."( The lectin Griffonia simplicifolia I-A4 (GS I-A4) specifically recognizes terminal alpha-linked N-acetylgalactosaminyl groups and is cytotoxic to the human colon cancer cell lines LS174t and SW1116.
Boland, CR; Chen, YF; Goldstein, IJ; Kraus, ER, 1994
)
0.29
" Chronic weekly dosing resulted in sustained dose-dependent gene silencing for over 9 months with no adverse effects in rodents."( Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.
Akinc, A; Alam, MR; Chan, A; Charisse, K; Fitzgerald, K; Hoekstra, M; Hutabarat, R; Jung, ME; Kandasamy, P; Kel'in, AV; Kuchimanchi, S; Maier, MA; Manoharan, M; Milstein, S; Nair, JK; O'Shea, J; Rajeev, KG; Shaikh, S; Taneja, N; van Berkel, TJ; van der Sluis, RJ; Wang, Q; Willoughby, JL; Zhang, L; Zimmermann, T, 2014
)
0.76
" Greater and more sustained reductions in ALA and PBG were achieved with once monthly dosing compared with once quarterly dosing."( Pharmacokinetics and Pharmacodynamics of the Small Interfering Ribonucleic Acid, Givosiran, in Patients With Acute Hepatic Porphyria.
Agarwal, S; Clausen, VA; Goel, V; Habtemariam, BA; Kim, JB; Robbie, GJ; Simon, AR, 2020
)
0.56
" Four male rats per group were dosed once, 3, or 6 times subcutaneously, with 7 days between dosing, and sacrificed 3 days after the last dose."( Safety, Tissue Distribution, and Metabolism of LNA-Containing Antisense Oligonucleotides in Rats.
Braendli-Baiocco, A; Brink, A; Dzygiel, P; Festag, M; Fischer, G; Hetzel, U; Husser, C; Kipar, A; Koller, E; Lenz, B; Mihatsch, MJ; Romero-Palomo, F; Schadt, S; Sewing, S; Steinhuber, B; Tessier, Y; Winter, M, 2021
)
0.62
" The sustained efficacy of givosiran in most patients allowed us to personalize dosing frequency."( Givosiran in acute intermittent porphyria: A personalized medicine approach.
Bouchoule, I; Cerutti, D; Douillard, C; Duchêne, F; Dupré, T; Faivre, A; Fiorentino, V; Gouya, L; Grobost, V; Lefebvre, T; Manceau, H; Mirmiran, A; Moulouel, B; Peoc'h, K; Poli, A; Puy, H; Rivière, S; Schmitt, C; Talbi, N, 2022
)
0.72
"The sustained effect of givosiran allowed a decrease in dosing frequency without compromising treatment efficacy."( Givosiran in acute intermittent porphyria: A personalized medicine approach.
Bouchoule, I; Cerutti, D; Douillard, C; Duchêne, F; Dupré, T; Faivre, A; Fiorentino, V; Gouya, L; Grobost, V; Lefebvre, T; Manceau, H; Mirmiran, A; Moulouel, B; Peoc'h, K; Poli, A; Puy, H; Rivière, S; Schmitt, C; Talbi, N, 2022
)
0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
N-acetyl-D-galactosamineThe D-enantiomer of N-acetylgalactosamine.
N-acetylgalactosamine
N-acetyl-D-hexosamineAny N-acetylhexosamine in which the hexosamine has D-configuration. The structure provided is an illustrative example of the pyranose form of an N-acetyl-D-hexosamine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (19)

PathwayProteinsCompounds
Metabolism14961108
Amino acid and derivative metabolism250260
Selenoamino acid metabolism2450
Formation of selenosugars for excretion011
chondroitin sulfate degradation (metazoa)03
dermatan sulfate degradation (metazoa)03
chondroitin sulfate and dermatan sulfate degradation I (bacterial)09
Carbohydrate metabolism173120
Glycosaminoglycan metabolism3637
Keratan sulfate/keratin metabolism918
Keratan sulfate degradation19
Chondroitin sulfate/dermatan sulfate metabolism1215
CS/DS degradation37
Metabolism of lipids500463
Sphingolipid metabolism5550
Glycosphingolipid metabolism3031
Renz2020 - GEM of Human alveolar macrophage with SARS-CoV-20490
5q35 copy number variation012
Glycosphingolipid catabolism1716

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain 1, MANNOSE-BINDING PROTEIN-ARattus norvegicus (Norway rat)Kd200.0000200.0000200.0000200.0000AID977611
Chain A, Galacto-N-biose/lacto-N-biose I transporter substrate-binding proteinBifidobacterium longumKd0.01000.01000.01000.0100AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
protein bindingFibrinogen C domain-containing protein 1Homo sapiens (human)
chitin bindingFibrinogen C domain-containing protein 1Homo sapiens (human)
metal ion bindingFibrinogen C domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
membraneFibrinogen C domain-containing protein 1Homo sapiens (human)
collagen-containing extracellular matrixFibrinogen C domain-containing protein 1Homo sapiens (human)
extracellular spaceFibrinogen C domain-containing protein 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID501262Inhibition of rat recombinant NKR-P1A receptor expressed in Escherichia coli by beta-scintillation counting relative to control2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Synthetic N-acetyl-D-glucosamine based fully branched tetrasaccharide, a mimetic of the endogenous ligand for CD69, activates CD69+ killer lymphocytes upon dimerization via a hydrophilic flexible linker.
AID450448Activity of Escherichia coli O55:H7 glycosyltransferase WbgO by Lineweaver-Burke analysis2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Characterization and synthetic application of a novel beta1,3-galactosyltransferase from Escherichia coli O55:H7.
AID39236Inhibition of Asialoglycoprotein receptor mediated uptake of [125I]-ASOR at 37 degrees Centigrade by hepatocytes1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor.
AID450450Activity of Escherichia coli O55:H7 glycosyltransferase WbgO2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Characterization and synthetic application of a novel beta1,3-galactosyltransferase from Escherichia coli O55:H7.
AID39235Affinity towards Asialoglycoprotein receptor using in vitro competition assay for [125I]- ASOR binding to the parenchymal liver cells of rat1995Journal of medicinal chemistry, Apr-28, Volume: 38, Issue:9
Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor.
AID450449Ratio of Kcat to Km for Escherichia coli O55:H7 glycosyltransferase WbgO by Lineweaver-Burke analysis2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Characterization and synthetic application of a novel beta1,3-galactosyltransferase from Escherichia coli O55:H7.
AID450447Activity of Escherichia coli O55:H7 glycosyltransferase WbgO relative to GlcNAc2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Characterization and synthetic application of a novel beta1,3-galactosyltransferase from Escherichia coli O55:H7.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1998The Journal of biological chemistry, Jul-31, Volume: 273, Issue:31
Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain.
AID1811Experimentally measured binding affinity data derived from PDB1998The Journal of biological chemistry, Jul-31, Volume: 273, Issue:31
Mechanism of N-acetylgalactosamine binding to a C-type animal lectin carbohydrate-recognition domain.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008The Journal of biological chemistry, May-09, Volume: 283, Issue:19
Structural and thermodynamic analyses of solute-binding Protein from Bifidobacterium longum specific for core 1 disaccharide and lacto-N-biose I.
AID381593Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutinination relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381595Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutinination relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381592Anticryptosporidial activity against Cryptosporidium parvum GCH1 assessed as inhibition of rabbit erythrocytes hemagglutinination2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID452767Inhibition of D-GalNAc-PAA binding to human recombinant ASGPR1 carbohydrate recognition domain expressed in Escherichia coli AD494 by competitive solid-phase binding assay relative to D-GalNAc2009Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
AID381597Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells relative to galactose2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381596Inhibition of Cryptosporidium parvum recombinant Galactose/N-acetylgalactosamine-specific lectin binding to Caco2A cells2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
AID381594Anticryptosporidial activity against Cryptosporidium hominis TU502 assessed as inhibition of rabbit erythrocytes hemagglutinination2007The Journal of biological chemistry, Nov-30, Volume: 282, Issue:48
Cryptosporidium p30, a galactose/N-acetylgalactosamine-specific lectin, mediates infection in vitro.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,691)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990508 (30.04)18.7374
1990's423 (25.01)18.2507
2000's310 (18.33)29.6817
2010's318 (18.81)24.3611
2020's132 (7.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 59.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index59.88 (24.57)
Research Supply Index7.47 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index103.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (59.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials15 (0.86%)5.53%
Reviews0 (0.00%)6.00%
Reviews63 (3.62%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies17 (0.98%)4.05%
Observational0 (0.00%)0.25%
Observational2 (0.12%)0.25%
Other8 (100.00%)84.16%
Other1,642 (94.42%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]